Heart Failure Nursing Guide 2026
⚕️ Medical Disclaimer: This content is for educational purposes only and is intended for licensed healthcare professionals. It does not constitute medical advice and should not replace clinical judgment, facility protocols, or physician orders. Always verify medications, doses, and procedures with your institution's guidelines.
Part of the ICU Emergencies Hub — browse every related guide in one place.
This article was created with AI assistance.
HFrEF vs HFpEF pathophysiology, NYHA stages, BNP-guided fluid management, inotropes, diuretics, patient education, and all the NCLEX-essential heart failure nursing pearls.
1. Heart Failure Basics
Heart failure (HF) = the heart cannot pump enough blood to meet the body's needs, OR can only do so at elevated filling pressures. Two main types:
| Feature | HFrEF (Reduced EF — "systolic") | HFpEF (Preserved EF — "diastolic") |
|---|
| EF | <40% | ≥50% (40–49% = borderline/HFmrEF) |
| Problem | Ventricle doesn't squeeze hard enough (reduced contractility) | Ventricle too stiff to relax and fill (impaired relaxation/compliance) |
| Common causes | MI (most common), cardiomyopathy, longstanding hypertension, valvular disease | Hypertension (most common), diabetes, obesity, A-Fib, aging |
| Treatment options | ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i + device therapy (ICD/CRT) | Treat underlying causes; diuretics for congestion; SGLT2i (empagliflozin) shown to reduce HF hospitalizations; limited specific therapies |
2. NYHA Functional Classification
| Class | Description | Clinical Example |
|---|
| Class I | No symptoms with ordinary activity; no limitation | Asymptomatic; HF diagnosis on echo/labs only |
| Class II | Mild — slight limitation; comfortable at rest; ordinary activity causes symptoms | Walks 2 blocks then gets short of breath |
| Class III | Moderate — marked limitation; comfortable at rest; less than ordinary activity causes symptoms | SOB walking from bedroom to bathroom; cannot climb stairs |
| Class IV | Severe — symptoms at rest; any physical activity worsens symptoms | SOB at rest; cannot lie flat (orthopnea); severe edema |
3. ACC/AHA Stages (Structural)
| Stage | Description |
|---|
| A | High risk for HF but no structural disease or symptoms (hypertension, DM, family history) |
| B | Structural disease but no symptoms (previous MI, reduced EF, asymptomatic valvular disease) |
| C | Structural disease with prior or current HF symptoms — majority of patients |
| D | Refractory HF — advanced therapies needed (VAD, transplant, hospice) |
4. Assessment: Signs and Symptoms
Left-Sided HF (Pulmonary Congestion)
Left heart failure → blood backs up into lungs
- Dyspnea on exertion (earliest symptom) → progresses to dyspnea at rest
- Orthopnea: shortness of breath when lying flat (ask: how many pillows to sleep?)
- Paroxysmal nocturnal dyspnea (PND): wakes from sleep acutely short of breath, improves when sits upright
- Pulmonary crackles (rales) — bilateral basilar
- Pulmonary edema (severe): pink frothy sputum, severe respiratory distress, SpO2 drop
- S3 gallop: extra heart sound in early diastole = volume overload, reduced EF (hallmark of HFrEF)
- Tachycardia (compensatory)
Right-Sided HF (Systemic Venous Congestion)
Right heart failure → blood backs up into body
- Jugular venous distension (JVD): elevated CVP/JVP; assess at 45° — >3 cm above clavicle is elevated
- Dependent pitting edema: bilateral ankle/foot edema (worse in evening), progresses to sacral edema in bedbound
- Hepatomegaly + hepatojugular reflux (HJR) — apply pressure to RUQ → JVD increases
- Ascites: fluid accumulation in peritoneum
- Nausea/anorexia: gut congestion impairs absorption
- Weight gain: 1 kg = 1 liter fluid retention
5. Diagnostic Tests
| Test | Findings in HF | Clinical Use |
|---|
| BNP (B-type natriuretic peptide) | >100 pg/mL likely HF; >400 = high probability; <100 = unlikely HF if SOB | Rule in/out HF; guide diuresis; monitor response to treatment |
| NT-proBNP | Age-adjusted cutoffs: >450 pg/mL (age <50), >900 (50–75), >1800 (age >75) | Same as BNP; longer half-life; less affected by acute changes |
| Echocardiogram | EF%, wall motion, valvular function, estimated filling pressures, LV/RV size | Diagnose and classify HF type; guide therapy |
| Chest X-ray | Cardiomegaly (heart >50% thorax width on PA), pulmonary vascular congestion ("cephalization"), Kerley B lines, pleural effusion, "bat wing" pattern in pulmonary edema | Quick assessment of fluid status and cardiac size |
| BMP (electrolytes) | Hyponatremia (poor prognosis), elevated creatinine (cardiorenal syndrome), hyperkalemia (ACE inhibitor/MRA effect) | Guide fluid and medication management |
BNP vs NT-proBNP: BNP is the active hormone; NT-proBNP is the inactive fragment. Both rise with heart failure. Note: BNP is lower in obese patients (stored in fat tissue); BNP elevated by: HF, PE, cor pulmonale, renal failure. BNP NOT elevated by: simple hypertension without HF, pericardial disease (tamponade actually lowers BNP).
6. Acute Decompensated HF (ADHF) Management
Initial Assessment and Hemodynamic Profile
The Forrester classification profiles ADHF by warm/cold (perfusion) and wet/dry (congestion):
- Warm and Wet (most common): good perfusion, congested → diuresis is primary treatment
- Cold and Wet: poor perfusion + congestion → cautious diuresis + inotropes + possibly vasodilators
- Cold and Dry: cardiogenic shock without congestion → IV fluids carefully + inotropes + vasopressors
- Warm and Dry: compensated euvolemic → optimize oral medications, prepare for discharge
Diuretic Therapy
Loop Diuretics (First-Line for Congestion):
- Furosemide (Lasix): IV dose should be ≥ patient's home oral dose × 2.5 (e.g., home 40 mg PO daily → give 80–100 mg IV). Goal: UO 3–5 mL/kg/hr for first 6 hr.
- Monitor: UO q1h, daily weights (morning, same scale, same clothes), BMP q12–24h (hypokalemia, hypomagnesemia, rising creatinine = AKI)
- Thiazide (metolazone) before furosemide for diuretic resistance: give 30–60 min before loop diuretic for synergistic effect
- Furosemide bolus vs infusion: continuous infusion preferred for severe congestion (more consistent diuresis, less ototoxicity risk)
Furosemide ototoxicity: High-dose IV furosemide given rapidly → hearing loss (tinnitus → deafness). Infuse no faster than 4 mg/min (single doses >40 mg); use infusion for high doses. Concurrent aminoglycosides greatly increase risk.
Vasodilators
| Drug | Mechanism | Use in HF | Caution |
|---|
| Nitroprusside | Arterial + venous dilation (balanced) | Hypertensive HF, cardiogenic shock (reduces afterload) | Cyanide toxicity with prolonged use; thiocyanate level monitoring; only in ICU with arterial line |
| Nitroglycerin (IV) | Primarily venodilation (preload reduction); arterial at high doses | Pulmonary edema, hypertensive HF | Hypotension; headache; tolerance with continuous use; avoid in RV failure (RV depends on preload) |
| Nesiritide (BNP) | Venous + arterial dilation + natriuresis | Selected ADHF; reduces symptoms | Not shown to reduce mortality; use limited |
Inotropes (Cardiogenic Shock / Cold-Wet Profile)
| Drug | Mechanism | Dose | Use/Caution |
|---|
| Dobutamine | Beta-1 agonist → increased contractility and HR | 2–20 mcg/kg/min IV | Increases myocardial oxygen demand; arrhythmogenic; tachycardia; avoid in obstructive cardiomyopathy (HOCM) |
| Milrinone | Phosphodiesterase-3 inhibitor → increases contractility + vasodilation | 0.125–0.75 mcg/kg/min IV | Renal-dosed; more vasodilation than dobutamine; arrhythmias; may worsen outcomes in ischemic cardiomyopathy |
| Dopamine | Dose-dependent: 1–3 mcg/kg/min (renal); 3–10 (beta-1); >10 (alpha-1) | Variable | "Renal dose" dopamine NOT proven to protect kidneys; largely replaced by specific vasopressors/inotropes |
7. Guideline-Directed Medical Therapy (HFrEF)
These four drug classes are proven to reduce mortality in HFrEF (EF <40%):
- ACE inhibitor (lisinopril, enalapril) or ARB (losartan, valsartan) or ARNI (sacubitril/valsartan = Entresto) — Entresto preferred over ACEi when tolerated; do not combine ACEi + ARB (hyperkalemia, AKI)
- Beta-blocker (carvedilol, metoprolol succinate, bisoprolol — only evidence-based ones) — start LOW, titrate slowly; do NOT start in acute decompensation or when patient is "wet"
- Mineralocorticoid receptor antagonist (MRA) — spironolactone or eplerenone; watch for hyperkalemia and AKI
- SGLT2 inhibitor (dapagliflozin, empagliflozin) — reduces HF hospitalizations and cardiovascular death; also beneficial in HFpEF
Starting beta-blockers in HF: NEVER start when patient is decompensated (wet/edematous). Start when patient is "dry" and clinically euvolemic. Beta-blockers in the short term reduce contractility — they're beneficial only when started when the patient can tolerate the initial negative inotropy.
8. Nursing Monitoring
Daily Assessment
- Daily weight: Same time (AM), same scale, same clothing. Gain >1 kg (2 lb) in 24 hr or >2 kg (5 lb) in 1 week = call provider; adjust diuretics per parameters
- Fluid balance: Strict I&O; fluid restriction if ordered (typically 1.5–2 L/day in symptomatic HF)
- Electrolytes: Monitor daily — diuresis causes K+, Mg2+ depletion; ACEi/MRA can cause hyperkalemia
- Renal function (BMP): Creatinine may rise with aggressive diuresis — cardiorenal syndrome
- Lung sounds: Crackles clearing = responding to diuresis; new crackles = decompensating
- Edema: Document pitting scale (1+ through 4+), location, pitting depth
- JVD: Assess at 45° — elevation indicates persistent volume overload
- SpO2: Goal ≥95%; supplemental O2 as needed
- Blood pressure and HR: Guide medication titration (hold ACEi if SBP <90; hold beta-blocker if bradycardia)
9. Patient Education
Heart failure self-management (30-day readmission prevention):
- Weigh daily, same time, same scale — call provider if gain >2 lbs in 24 hr or >5 lbs in 1 week
- Fluid restriction as ordered (usually 1.5–2 L/day total fluids)
- Low-sodium diet: <2,000 mg/day (2 g) — no added salt, avoid processed/canned foods
- Take all medications as prescribed — especially ACEi and beta-blockers (do not stop beta-blockers abruptly)
- No NSAIDs (ibuprofen, naproxen) — cause fluid retention, reduce diuretic effect, worsen renal function
- Limit alcohol (dilated cardiomyopathy);
- Daily activity as tolerated; cardiac rehabilitation when appropriate
- Call provider if: weight gain, increased swelling, increased shortness of breath, worsening fatigue, dizziness
- Go to ER if: severe shortness of breath at rest, chest pain, syncope, cannot lie flat
NCLEX High-Yield Heart Failure Points
- HFrEF = EF <40% (systolic dysfunction); HFpEF = EF ≥50% (diastolic dysfunction)
- Left HF → pulmonary congestion (crackles, orthopnea, PND, S3 gallop)
- Right HF → systemic venous congestion (JVD, edema, hepatomegaly, ascites)
- S3 gallop = volume overload = HFrEF hallmark
- BNP >100 pg/mL = HF likely; <100 = HF unlikely (if SOB of unknown cause)
- Daily weight: report gain >2 lbs in 24 hr or >5 lbs in 1 week
- Furosemide: monitor potassium (hypokalemia) and creatinine (AKI)
- Beta-blockers for HF: do NOT start during acute decompensation (when wet)
- Patient education: low-sodium diet (<2g/day), daily weights, avoid NSAIDs
- ACEi/ARB + MRA (spironolactone) = watch for hyperkalemia
Get the ICU Notebook
Free investing strategies built for nurses. One email per week, no fluff.
Yes, send it free
No spam. Unsubscribe any time.